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ABSTRACT
Inflammatory breast cancer (IBC) is a unique and deadly disease with unknown 
drivers. We hypothesized the inflammatory environment contributes to the IBC 
phenotype. We used an in vitro co-culture system to investigate interactions 
between normal and polarized macrophages (RAW 264.7 cell line), bone-marrow 
derived mesenchymal stem cells (MSCs), and IBC cells (SUM 149 and MDA-IBC3). We 
used an in vivo model that reproduces the IBC phenotype by co-injecting IBC cells 
with MSCs into the mammary fat pad. Mice were then treated with a macrophage 
recruitment inhibitor, anti-CSF1. MSC and macrophages grown in co-culture produced 
higher levels of pro-tumor properties such as enhanced migration and elevated IL-6 
secretion. IBC cells co-cultured with educated MSCs also displayed enhanced invasion 
and mammosphere formation and blocked by anti-IL-6 and statin treatment. The 
treatment of mice co-injected with IBC cells and MSCs with anti-CSF1 inhibited tumor 
associated macrophages and inhibited pSTAT3 expression in tumor cells. Anti-CSF1 
treated mice also exhibited reduced tumor growth, skin invasion, and local recurrence. 
Herein we demonstrate reciprocal tumor interactions through IL-6 with cells found 
in the IBC microenvironment. Our results suggest IL-6 is a mediator of these tumor 
promoting influences and is important for the IBC induced migration of MSCs. 
INTRODUCTION
Inflammatory breast cancer is a deadly variant 
of breast cancer that presents with skin changes on the 
breast and spreads rapidly as a local, diffuse, “brush-
fire” through the breast and adjacent tissue. These signs 
are caused in part by blockage of lymphatics and skin 
invasion, not by classic inflammation [1]. To date, studies 
comparing IBC and non-IBC tumor cells have identified 
more similarities than differences. Our preliminary studies 
of non-tumor containing breast tissue at least 5 cm away 
from IBC tumor cells (normal adjacent tissue or the 
“field”) have identified interesting differences, however. 
One such difference is that that the number of CD 68+ cells 
identified by a pathologist as histologically macrophages 
was significantly elevated in IBC normal adjacent 
tissues compared to non-IBC [2, unpublished data]. We 
hypothesized that the normal breast phenotype including, 
macrophage infiltration and resultant interactions with 
MSC, perhaps prior to tumor initiation, may contribute to 
the unusual presentation of IBC.  
Macrophages are plastic cells broadly and 
simplistically characterized on a spectrum from 
Th1 stimulated pro-inflammatory to Th2 stimulated, 
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anti-inflammatory [3]. Tumor associated macrophages are 
prognostic in non-IBC and have been shown in vivo to 
promote lymphatic emboli, the hallmark of IBC [4]. The 
state and plasticity of macrophages (tumor associated or 
normal adjacent) in IBC models or patients and models 
has not been examined, nor has their interaction with other 
cell types in the IBC stroma. Such knowledge is important 
because these cells are potentially mediators of field 
effects that lead to the clinical characteristics of IBC, and 
therefore may be targets for treatment of IBC.
We have shown that mammosphere cultured MSCs 
promote tumor stem cells and in vivo growth [5], and 
Liu et al have shown that ALDH1+ MSCs do the same 
[6]. MSCs have also been demonstrated to mediate 
macrophage polarization and function [7]. Yet, the impact 
of macrophages on MSCs has largely been overlooked.
We hypothesized that pre-malignant macrophage-
educated MSCs in the breast mediate the IBC phenotype 
including diffuse migration, skin involvement, and 
treatment resistance. This hypothesis is based on our data 
demonstrating obvious macrophage infiltrates specifically 
in IBC normal adjacent tissue, unique spatial distribution 
of stem cells in the adjacent normal tissue of IBC, in vitro 
and in vivo data demonstrating MSCs promote stem cell 
surrogates and skin invasion of IBC, as well as published 
studies highlighting the role of macrophage-educated 
MSCs in supporting the hematopoietic stem cell niche. 
Herein we demonstrate macrophages are essential for 
the MSC promotion of skin invasion in the SUM149 
model and that these interactions are dependent on IL-6 
signaling.
RESULTS
Characterizing the interactions between MSCs 
and macrophages in a co-culture system
To characterize the effect on MSC activation of 
macrophages, we cultured RAW 264.7 mouse macrophage 
cells with human-derived MSC cells in an in vitro 
transwell co-culture assay (Figure 1). The transwell setting 
allowed us to investigate the effect of soluble mediators 
between different cell types since direct cell contact of 
these cells was inhibited by a polyethylene membrane. 
The MSCs co-cultured with M2 macrophages migrated 
at an almost 2-fold increase on average compared to 
MSCs grown with serum alone, M0, or M1 macrophages 
(p < 0.05) (Figure 2A). Next, we examined the impact 
of MSCs on macrophage polarization. Un-stimulated 
macrophage cells were cultured in vitro for 24 hours in 
regular RAW media or MSC conditioned media (CM) 
and then collected for flow cytometry analysis for CD206 
and Arginase-1, markers for M2 phenotype. MSC CM 
increased the percentage of CD206 and Arginase-1 
compared with control macrophages (Figure 2B). We next 
performed a luminex bead-based multiplex cytokine assay 
to evaluate the cytokine profile of MSCs. The levels of 
IL-6 in the MSC media was several fold higher than all 
the other cytokines assessed (Supplementary Table S1). 
Furthermore, the MSC2-educated cells secreted 1.6 fold 
more IL-6 compared to MSCs or MSC1 educated cells 
(p < 0.05) (Figure 2C). To investigate how MSCs co-
cultured with M2 macrophages impact MSC migration, 
we took MSC controls or MSC2-educated cells and 
transferred them to a co-culture system with two IBC cell 
lines (SUM 149 or IBC3) for 24 hours. We found MSC2 
educated cells co-cultured with either of the IBC cell lines 
exhibit greater migration towards tumor cells compared 
with uneducated control MSCs (p < .05). This observed 
effect could be reversed with the addition of an anti-
IL-6 neutralizing antibody during the 24 hour co-culture 
(Figure 2D). 
Crosstalk between MSC2-educated cells and IBC 
cells increases IBC invasion and self-renewal 
through IL-6
We next investigated how the IBC cells would 
respond following 24 hours co-culture with MSC2s. The 
IBC cells co-cultured with MSC2s had a significant higher 
number of invading cells compared with co-culture with 
serum alone or MSCs (Figure 3A). IBC3 cells grown in 
co-culture with MSC2s had a 3 fold increase in invasion 
compared with serum alone (Figure 3B). The increase in 
invasion of M2 educated-MSCs was inhibited with the 
addition of the anti-IL-6 antibodies during the co-culture 
(Figure 3A, 3B). We next assessed IBC mammosphere 
formation following co-culture. Co-culture with both 
MSCs and M2-educated MSC2s increased SUM149 
and IBC3 sphere formation efficiency. However, MSC2s 
increased sphere formation more strongly compared with 
control MSCs (Figure 3C, 3D). Once again this effect 
on mammosphere formation was blocked with anti-IL6 
antibodies (Figure 3C, 3D). 
Simvastatin inhibits MSC IL-6 secretion and 
inhibits the effects of M2 educated-MSCs on IBC 
invasion and self-renewal 
Studies have shown the cholesterol lowering drugs, 
statins, promote the pro-inflammatory macrophage 
subtypes and reduce the release of IL-6 in smooth 
muscular cells [8, 9]. We therefore tested the effects of 
simvastatin in our co-culture system. As seen before, 
MSC2s secreted more IL-6 compared with MSCs, while 
simvastatin reduced by over 2-fold the secretion of IL-6 in 
MSCs and MSC2s (Figure 4A). We next pre-treated MSCs 
or MSC2s with simvastatin or DMSO for 4 hours and then 
co-cultured the treated or untreated MSCs with IBC cells. 
As observed before, MSC2s significantly increased the 
number of mammospheres and invading cells of SUM 149 
cells following 24 hour co-culture. The treatment of the 
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Figure 1: Model of Co-Culture System. Macrophages were polarized with either LPS or IL-4 to become M1 or M2 macrophages 
respectively. Using a Boyden chamber MSCs were seeded with M1 or M2 macrophages for 24 hours to become either MSC1s or MSC2s. 
MSC1s or MSC2s were then co-cultured in Boyden chambers with IBC cells for 24 hours. Following co-culture MSCs and IBC cells were 
analyzed for migration, invasion, and mammosphere formation.
Figure 2: MSCs and macrophages cross-talk through IL-6. Following co-culture of with either un-polarized (M0), LPS induced 
(M1), or IL-4 induced (M2), and MSCs for 24 hours, (A) the number of MSCs that passed through the transwell membrane after 24 hours 
was counted. Significant differences are shown as follows: *P < 0.05 for unpaired 2-tailed Student's t-test (n = 3). (B) Macrophages were 
grown in the presence of MSC conditioned media (CM) for 24 hours and then stained with either anti-CD206 or anti-arginase-1 antibodies 
and submitted for flow cytometry analysis. (C) Following 24 hours of co-culture with macrophages and MSCs, supernatant was collected 
for IL-6 ELISA. (D) MSC or MSC2s were co-cultured with SUM149 and IBC-3 cells for 24 hours with or without anti-IL6 antibodies. The 
number of MSCs that passed through the transwell membrane after 24 hours was counted. Significant differences are shown as follows: 
*P < 0.05 for unpaired 2-tailed Student's t-test (n = 3).
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MSC2s with simvastatin prior to co-culture with SUM149 
cells inhibited both invasion and mammosphere formation 
of SUM 149 cells (4B, 4C). The addition of recombinant 
IL-6 reversed the above inhibition (Figure 4B, 4C). These 
results suggest simvastatin blocks MSC2 activation of IBC 
cells through reduction of IL-6.
Inhibiting tumor associated macrophage 
recruitment in an in vivo IBC model delayed 
tumor formation and decreased skin invasion 
and local recurrence and decreased pSTAT3
Colony stimulating factor-1 (CSF1) is a key 
cytokine involved in recruitment and activation of tissue 
macrophages [10]. Denardo et al showed an antibody 
against CSF1 blocked the binding of CSF1 to its CSF1 
receptor and inhibited tumor associated macrophages 
(TAM) within the breast tumor [11]. The co-injection 
of both SUM149 cells and human bone marrow derived 
MSCs injected into the mammary fat pad was previously 
shown to replicate the pathologically and phenotypical 
characteristics seen in human IBC patients [12]. A model 
of our in vivo experiment is represented in Figure 5A. 
Mice were co-injected with SUM149 and MSCs into the 
mammary cleared fat pad on day 0. On day 7 treatment 
with either anti-CSF1 antibody or IgG IP was started and 
continued weekly. Monitoring tumor growth we observed 
that tumor latency was significantly shorter in the IgG 
mice (68.3 days vs. 124.4 days, P < .001; Figure 5B). 
The time to reach tumor resection in the anti-CSF1 was 
slower than tumors in the IgG group (105.7 days vs. 209.3 
days, P < 0.001; Figure 5B). At the time of resection we 
recorded whether or not the tumor involved the skin as 
described in methods. The group of mice treated with anti-
CSF1 had significantly fewer mice with skin symptoms 
compared to the IgG group (7/10 IgG vs 1/10 anti-CSF1 
p = 0.02). Further, following resection we monitored 
for local recurrence using live bioimaging to detect 
luciferase signal 6 weeks following surgery. The IgG 
group had significantly more events of local recurrence 
compared to the anti-CSF1 group (9/10 IgG vs 4/10 anti-
CSF1 p = 0.05) (Figure 5C). The tumors were collected 
following resection and stained with macrophage specific 
antibodies F4/80 and the M2 marker CD206 and analyzed 
Figure 3: Crosstalk between educated MSCs and IBC cells increases IBC invasion and self-renewal through IL-6. 
Following 24 hours of co-culture with M2 macrophages, the "educated" MSC2s or parental MSCs were co-cultured with (A) SUM149 or 
(B) MDA-IBC3 for 24 hours with or without anti-IL6 antibodies. The number of IBC cells that invaded through the basement membrane 
transwell after 24 hours was counted. Significant differences are shown as follows: *P < 0.05 for unpaired 2-tailed Student's t-test (n = 3). 
(C) SUM149 or (D) MDA-IBC3 cells were co-cultured with MSC or MSC2s for 24 hours with or without anti-IL6 antibodies. IBC 
cells were then seeded in self-renewal mammosphre media promoting suspension culture conditions. Significant differences are shown as 
follows: *P < 0.05 for unpaired 2-tailed Student's t-test (n = 3).
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by flow cytometry. The anti-CSF1 group had a lower 
percentage of F4/80+ cells compared to the IgG group 
(Figure 5D). The anti-CSF1 group had a significantly 
lower percentage of double positive cells F4/80+ CD206+ 
cells, or TAMs, compared to the IgG group (p < .01) 
(Figure 5E). This suggests the anti-CSF1 antibody 
treatment in vivo reduced tumor macrophage recruitment 
and specifically blocked type 2 macrophage recruitment 
into the tumor and thus delaying tumor growth and skin 
invasion, hallmarks of IBC.
The binding of IL-6 to its receptor gp130 activates 
JAK2 which goes on to activate several downstream 
tumor promoters such as STAT3. Phosphorylated STAT3 
(pSTAT3) activates cell survival factors and promoters of 
cell proliferation such as c-myc [13]. We next determined 
whether blocking macrophage recruitment in the above 
in vivo experiment reduced IL-6 secretion within the tumor 
environment by measuring pSTAT3 in the tumor samples. 
Examination of a cellular view, showed the IgG group had 
higher nuclear staining of pSTAT3 compared with the anti-
CSF1 group (Figure 6A). The number of nuclei staining for 
pSTAT3 and the mean intensity of pSTAT3 staining was 
significantly higher in the IgG control group (Figure 6B). 
DISCUSSION
Macrophages are a major component of the innate 
immunity and are distributed throughout every tissue. 
After circulating monocytes differentiate into macrophages 
they invade into tissues and increase immune reactions 
to the response of injury [14]. In addition, macrophages 
remove cellular debris and clear dead or apoptotic cells 
[15]. Macrophages can be polarized in the environment 
in response to different stimuli [16]. The two classes of 
polarized macrophages are classically activated (M1) 
alternatively-activated (M2) macrophages [17]. M1 and 
M2 secrete different cytokines, and M2 is known to 
secrete IL-10, TNF-α and IL-6 [18]. 
Figure 4: Simvastatin blocks IL-6 secretion and inhibits the effects of M2 educated MSCs on IBC invasion and 
self-renewal. (A) MSC or MSC2s were treated with DMSO (control) or simvastatin for 4 hours and the supernatant was submitted for 
IL-6 ELISA. MSCs and MSC2s were either pre-treated with simvastatin or simvastatin plus IL-6 for 4 hours then co-cultured with SUM149 
cells for 24 hours. (B) Following co-culture the number of SUM149 cells that invaded through the basement membrane transwell after 
24 hours was counted. (C) SUM149 cells were seeded in self-renewal promoting suspension culture conditions. Significant differences are 
shown as follows: *P < 0.05 for unpaired 2-tailed Student's t-test (n = 3).
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Upon addition of MSC CM to macrophages, we 
observed an increase in expression of cell surface marker 
CD206 and Arginase 1, markers of the M2 phenotype. 
Additional studies by Ortiz et al. showed MSC-
conditioned media inhibits the capacity of RAW- 264.7 
cells activated by silica or LPS to secrete TNFα [19], and 
Nemeth et al. investigated the effect of mouse BM-derived 
MSCs in a murine model of septicemia and showed LPS-
stimulated macrophages produced more IL-10 when co-
cultured with BM-derived MSCs [20]. In our study MSCs 
co-cultured with M2 macrophages secreted higher levels 
of IL-6. We speculate that the crosstalk between MSCs 
and M2 macrophages is a driver of the IBC phenotype. 
In fact, these MSC2s enhanced IBC cell invasion and 
mammosphere formation. IL-6 signaling in tumor cells 
increases tumor growth by promoting tumor invasiveness, 
metastasis and angiogenesis [21]. Secretion of IL-6 leads 
to recruitment of metastatic cells out of the circulation to 
the primary tumor sites [22]. 
In addition to the effects on the tumor itself, 
recent studies show IL-6 controls tumor growth by 
activating the normal stromal cells located in the tumor 
microenvironment. For example, STAT3 activation 
initiated by IL-6 in tumor-associated endothelial cells, 
TAM, and MSCs induces their ability to express VEGF 
and bFGF in a feed-forward loop that positively regulates 
angiogenesis within tumor tissues [23]. Recent evidence 
suggests that MSCs coordinate with tumor cells that 
triggers increased IL-6 production, which correlates with 
accumulation of MSCs [24].
In an in vivo study, the combined treatment of 
MMTV-PyMT mice with paclitaxel and anti-CSF1 
Figure 5: Inhibiting M2 macrophage recruitment in the in vivo IBC model inhibites IBC growth and skin invasion. (A) Cell 
suspensions of SUM149 cells and human bone marrow derived MSCs were prepared from monolayer cultures. In both groups, SUM149 and 
MSCs (9:1 ratio) were mixed and then co-injected into the mammary cleared fat pad as previously described. 24 hours following co-injection 
of tumor cells and MSCs, we started treatment with either anti-CSF1 antibody or IgG intraperitoneally. We continued with injections of these 
antibodies weekly up until the week before resection of the tumor. (B) Weekly tumor measurements were made. (C) The presence of skin 
invasion and following tumor resection the presence of local recurrence was recorded. Tumors from both groups were resected and collected for 
digestion. Tumor samples were either stained with (D) anti-F4/80 antibodies or (E) both anti-F4/80 and anti-CD206 antibodies. The results of 
3 replicates are shown by flow cytometry. Significant differences are shown as follows: *P < 0.05 for unpaired 2-tailed Student's t-test (n = 3).
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antibody slowed primary tumor development, reduced 
development of high-grade carcinomas, and decreased 
pulmonary metastasis by 85% and increased CD4+ 
and CD8+ T-cell infiltration in primary tumors. CSF1 
receptor blockade by PLX3397 depleted TAMs, but not 
neutrophils [25]. Similarly in our in vivo experiment, 
CSF1 inhibition delayed SUM149 tumor initiation and 
reduced the percentage of TAMs (F4/80+/CD206+ cells). 
Importantly since IBC is characterized by rapid skin 
involvement, the reduction we saw in MSC induced 
skin invasion is noteworthy. These results suggest that 
the induction of the IBC phenotype with the addition 
of MSC cells is mediated by the host’s macrophage 
infiltration, specifically M2 macrophages. Furthermore, 
pSTAT3 expression was inhibited by anti-CSF1 treatment 
suggesting that the inhibition of macrophage recruitment 
reduces the IL-6 signaling between MSCs and IBC cells. 
These data provide additional supportive evidence for a 
new clinical trial studying ruxolitinib (JAK inhibitor) in 
IBC (TBRCR trial # NCT02041429). Future studies are 
warranted looking drugs that can specifically target M2 
type macrophages in patients with IBC. Our preliminary 
data suggest statins would be a well-tolerated FDA 
approved drug to investigate. 
MATERIALS AND METHODS
Cell culture
The IBC cell line SUM149 was obtained from 
Asterand (Detroit, MI, USA) and cultured in Ham’s 
F-12 media supplemented with 10% fetal bovine serum 
(FBS), 1 mg/mL hydrocortisone, 5 mg/mL insulin, and 
1% antibiotic-antimycotic. MDA-IBC3 was generated 
in our lab and was described previously (Lacerda et al., 
PLoS One 2010) and was  cultured in Ham’s F-12 media 
supplemented with 10% fetal bovine serum (FBS), 1 µg/ml 
hydrocortisone, 5 µg/ml insulin and 1% antibiotic-
antimycotic.
Figure 6: Inhibiting tumor associated macrophages reduces expression of pSTAT3 in tumor samples (A) Stitched 
fluorescent image (20X) of IgG tissue staining for DAPI (blue) and pSTAT3 (red). (B) Hematoxylin and eosin stain of IgG 
tumor tissue with arrow showing tumor invasion into the muscular skin layer. (C) Multiplex image (20×) of anti-CSF-1 tumor tissue 
staining for DAPI (blue) and pSTAT3 (red). (D) Hematoxylin and eosin stain of anti-CSF1 tumor tissue showing high degree of necrosis and 
undifferentiation. (E) Representative fluorescent image (20×) of IgG and anti-CSF1 mouse showing DAPI, pSTAT3, and merged images. 
(F) Left: representative histogram of mean nuclear pSTAT3 intensity (background-subtracted) between IgG and anti-CSF-1 tumor nuclei 
distributions (nnuclei = 3000 in a single tissue section analyzed for each sample). Right: mean nuclear pSTAT3 intensity (background-
subtracted) across multiple mice (nIgG = 2 mice, nanti-CSF1 = 3 mice; 3 sections per mouse analyzed).
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 Human-derived bone marrow MSCs were 
obtained from EMD Millipore (Billerica, MA, USA) 
(Part #SCC034, Lot N61710996) and cultured in alpha 
minimum essential medium (αMEM) supplemented with 
20% FBS and 1% penicillin/streptomycin/glutamine. The 
mouse macrophage cell line RAW 264.7 was purchased 
from ATCC and maintained in Dulbecco's Modified Eagle 
Medium (DMEM) supplemented with 10% FBS. 
Transwell co-culture assay
5 × 104 of either breast cancer cells, macrophages, or 
MSCS were seeded in the lower compartment of 12 well 
transwell polyethylene terephthalate (PET) permeable 
supports in the 75 mm polycarbonate transwell inserts 
pore size 8 μm (Corning, Corning NY), respectively, 
and let to adhere overnight. The medium was replaced 
with serum free media one hour before adding 5 × 104 of 
breast cancer cells, macrophages, or MSCs into the upper 
compartment of the transwell inserts. The co-cultures 
were incubated for 24 hours without medium change in 
a humidified chamber at 37°C. Following 24 hours, cells 
at the bottom of the co-culture assay were transferred for 
further experiments. 
Macrophage and MSC polarization
Macrophage polarization was obtained by removing 
the culture medium and culturing cells for an additional 
24 h in DMEM media without FBS and 100 ng/ml LPS 
(for M1 polarization) or 20 ng/ml IL-4 and IL-13 (for 
M2 polarization). MSCs were plated at the bottom of the 
co-culture transwell system overnight. MSCs following 
24 hours of co-culture with M1 or M2 macrophages are 
described as M1-educated or M2-educated furthermore 
respectively (Figure 1). 
Migration and invasion assays
Cells were assayed for their ability to migrate or 
invade using the cytoselect 24 well Cell Migration and 
Invasion Assay Kit (Cell Bio Labs, San Diego, CA). The 
Cell Migration portion of this kit uses polycarbonate 
membrane inserts (8 µm pore size) in a 24- well plate. The 
membrane serves as a barrier to discriminate migratory 
cells from non-migratory cells. 5.0 × 104 of either MSCs, 
macrophages, or IBC cells were seeded in the top of the 
insert on the membrane. Serum free medium or one of the 
cell types was grown in the bottom of the transwell. After 
24 hours of incubation at 37°C in a 5% CO2 atmosphere, 
the membranes containing the cells were fixed and stained 
with crystal violet. The lower surfaces of the membranes 
were photographed at × 100 magnification. Five random 
fields were photographed for each chamber to determine 
the migration.
The Cell Invasion Assay portion of this kit uses a 
24-well plate containing polycarbonate membrane inserts 
(8 µm pore size); the upper surface of the insert membrane 
is coated with a uniform layer of dried basement 
membrane matrix solution. This basement membrane layer 
serves as a barrier to discriminate invasive cells from non-
invasive cells. Invasive cells are able to degrade the matrix 
proteins in the layer, and ultimately pass through the pores 
of the polycarbonate membrane. Finally, the cells are 
removed from the top of the membrane and the invaded 
cells are stained and quantified.
Sphere formation assay
5.0 × 104 of IBC cells were plated on the bottom of 
the transwell assay overnight. 5.0 × 104 MSCs or serum 
free medium were added to the insert. Following 24 hours 
of co-culture the IBC cells were transferred to standard 
mammosphere medium (serum-free, growth-factor-enriched 
medium) in low attachment plates at a concentration of 
20,000 cells/mL, incubated for 7 days, and counted.
IL-6 ELISA, IL-6, Anti-IL-6, and simvastatin 
treatment
IL-6 protein levels in culture supernatants were 
determined using commercial ELISA kits (eBioscience, 
San, Diego, CA). Recombinant human IL-6 and human 
IL-6 antibodies used to neutralize the binding of IL-6 to 
its receptor were purchased (R&D systems, Minneapolis, 
MN). IL-6 concentrations of 3 ng/mL and a concentration 
of 1 µg/mL of anti-IL-6 was used. Cells were exposed 
for 24 hours. Simvastatin (Sigma, St Louis, MO)) was 
dissolved in DMSO at a stock concentration of 5 mM and 
stored at −80°C, and a final concentration of 2.5 µM was 
used in this study. DMSO alone was used as a control.  
Flow cytometry
RAW macrophages were cultured in either RAW 
media described above or in conditioned media (CM) 
from MSCs for 24 hours. Following 24 hours 5 × 105 of 
RAW cells were washed twice with PBS containing 1% 
goat serum and resuspended with 10 μL of anti-mouse 
CD206 Alexa Fluor 647, Arginase 1 PE (AbD Serotec), 
and 40 μL of the 1% serum PBS buffer. For tumor samples 
collected in vivo, cells were digested and washed in PBS 
containing 1% goat serum and resuspended in 10 µL of 
anti-mouse F4/80 PE (Ebioscience) and CD206. For both 
assays, samples were incubated for 20 minutes on ice, 
washed with 1% serum PBS buffer, and analyzed with 
the FACSCalibur. Cells with an isotype control for each 
antibody were used to set up the gate for analysis. The 
data were analyzed by the FlowJo software (version 8.8.6; 
TreeStar, Inc.).
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Co-injection of SUM149 cells with MSCs
SUM149 cells were injected into the cleared 
mammary fat pads of female immunocompromised SCID/
Beige mice (3 to 5 weeks old), with MSCs (9:1 ratio), in 
a total of 2.5 × 105 cells per injection. For co-injections, 
2.5 × 104 MSCs were premixed with GFP-labeled SUM149 
cells and the mixture co-injected in the #4 (left side) 
mammary fat pad of the mice. Transplants were allowed to 
grow to 500 mm3 (monitored with caliper measurements) 
and were then resected in a survival surgery.
Follow-up of tumor-skin involvement and 
metastasis development
Tumor-skin involvement was accessed visually 
during primary tumor growth (loss of fur at tumor site, 
redness and thickness of skin) and during tumor excision 
(tumors firmly connected with skin). The development 
of local recurrences was monitored by bioimaging the 
luciferase signal (IVIS Spectrum system (Caliper Life 
Sciences, Hopkinton, MA, USA)). Findings between 
groups were compared with Fisher’s exact test.
In vivo treatment with anti-CSF1
After co-injection of SUM149 cells and 
MSCs into the cleared mammary fat pads of female 
immunocompromised SCID/Beige mice as described 
above, mice were injected intraperitoneally (IP) with 
either mouse IgG or anti-mouse CSF1 antibodies (clone: 
5A1, dose of 0.5 mg per injection) (BioXCell, West 
Lebanon, NH) started on day 7 following injection of cells 
and continued weekly up until the time of resection.
Immunofluorescence
5 µm thick formalin-fixed, paraffin-embedded 
xenograft cross-sections harvested from mice treated 
with anti-CSF1 or IgG were stained with antibody 
against pSTAT3 (1:400, Cell Signaling Technologies 
Inc.) and secondary antibody AlexaFluor 647 (1:200, 
Invitrogen, Molecular Probes Inc.) and with DAPI 
(1:1000). Sections were deparaffinized by two sequential 
baths of xylene followed by 100% ethanol, 95% ethanol, 
70% ethanol, and 30% ethanol. Antigen retrieval was 
performed using 1 mM EDTA (pH 8) in a 95˚C steamer 
for 20 minutes, followed by permeabilization with 0.2% 
Triton-X 100. Sections were blocked for 30 minutes in 
blocking solution containing 10% normal donkey serum 
(Jackson ImmunoResearch), 1% (w/v) BSA (Jackson 
ImmunoResearch), and 0.02% Triton X 100 in PBS. 
Primary antibody was incubated in 10% blocking solution. 
Epi-fluorescent images of stained slides were captured on 
a Nikon Ti-Eclipse microscope equipped with Luca-R 
camera using a 20× (0.95 NA) objective and images were 
saved using Nikon NIS Elements software.
Immunofluorescence quantification
After fluorescent images of DAPI and pSTAT3 were 
acquired, tumor cells were identified based on DAPI-
stained nuclei using texture analysis through ImageJ image 
analysis software (NIH). Nuclei were thresholded into 
regions of interest (ROIs) using built-in auto thresholding 
techniques, and then background-subtracted pSTAT3 
signal was overlaid on nuclear ROIs. Mean pSTAT3 
intensity within each ROI was measured using ImageJ in 
at least 3000 nuclei per section (n = 2 mice for anti-CSF1 
and n = 3 mice for IgG, with 3 blindly-chosen sections 
analyzed per mouse).
Statistical analysis
Statistical analysis and graphing were performed 
using MATLAB 2016a (Mathworks Inc.) and Prism 7.0 
(GraphPad Software Inc.). Mean pSTAT3 intensities were 
plotted on a histogram and representative distributions 
were generated for each condition (anti-CSF1 or IgG). A 
two-tailed t-test was used to analyze differences in mean 
pSTAT3 intensities between conditions (p < .05 statistical 
significance), with bar plot shown with mean ± SEM.
T-tests were performed using GraphPad Prism 
software, version 5.00 (GraphPad Software, San Diego, CA, 
www.graphpad.com) to determine statistically significant 
differences between groups. Differences were considered 
significant if p < 0.05. All graphs show mean ± SEM.
CONCLUSIONS
We demonstrate reciprocal tumor interactions 
between normal cells in the IBC microenvironment. MSC 
and macrophages can influence each other to increase 
the tumor promoting influence of each on IBC cells. Our 
results suggest IL-6 a mediator of these tumor promoting 
influences and is important for the IBC induced migration 
of MSCs. 
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